Pharmaceutical Executive
An answer to your question: What does the Part D coverage gap do to drug sales?
Keith Mandia
Advertisement
Articles by Keith Mandia
Advertisement
Latest Updated Articles
Inside the Doughnut HoleAugust 1st 2008
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5